← Eichor
Study identifier: NCT06856525 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Condition: Electronic Cigarette Related Lung Damage  ·  Sponsor: Y. Michael Shim, MD

PhasePhase 2/Phase 3
Planned participants80
Who can joinAll sexes, 18 Years to 35 Years
Healthy volunteersYes

About this study

A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of electronic cigarette use on pulmonary gas exchange capacity and then corroborate the Hyperpolarized Xenon MRI (HXeMRI) results with the cardiopulmonary stress test at the initial visit and a follow-up visit 12 months later.

This description comes directly from the study's public registry record.

Talk to the study team

Roselove Asare, MA  ·  4342436074  ·  rnn3b@virginia.edu

Caleigh Smith, BS  ·  434-243-1140  ·  RJT3QF@uvahealth.org

Always discuss trial participation with your own doctor first.

Locations (2)

Duke UniversityDurham, North Carolina, United StatesRecruiting
University of VirginiaCharlottesville, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06856525